Masimo Joins Forces with the Mobilize Recovery 2024 Bus Tour
Collaborative Partnership Designed to Enhance Nationwide Efforts to Combat the Opioid Epidemic and Improve Addiction Recovery
Masimo (NASDAQ: MASI), a leading global medical technology innovator, today announced that it is partnering with Mobilize Recovery, a nonprofit organization dedicated to ending America’s addiction and overdose crisis, by sponsoring and joining the Mobilize Recovery 2024 bus tour. The tour, which kicks off on September 20th in Los Angeles, with the first stop in Irvine, at the Masimo headquarters, is set to travel to 15 key cities around the U.S. to raise awareness, educate, and support communities around the country as they seek to prevent overdose and make sustainable improvements in addiction recovery outcomes. As part of this sixth annual initiative, Mobilize Recovery and Masimo will be showcasing two key Masimo innovations, Opioid Halo™ and Bridge™, which are designed to help people who are using opioids stay safe and reduce withdrawal symptoms during addiction recovery, respectively.
Founded by Mr. Ryan Hampton, Mobilize Recovery brings together recovery advocates, nonprofit organizations, allies, business leaders and innovators like Masimo, government partners, and like-minded community-based organizations with an interest in creating sustainable change and community solutions, as well as celebrating recovery from substance abuse disorder and mental health challenges. Engaging year-round with mobilizers, Mobilize Recovery provides partnership support and education to uplift and sustain partners’ work; help them develop action-oriented, measurable, scalable goals; raise public awareness; and prevent overdose.
Ryan Hampton, Founder and Executive Director of Mobilize Recovery, said, “Mobilize Recovery champions a grassroots approach, empowering advocates, innovators, businesses, and communities battling the overdose crisis firsthand. We see Masimo as a leading innovation partner in the recovery movement, uniquely positioned to drive technological advancements that make a real impact. We're thrilled to collaborate with a company so committed to leveraging technology for groundbreaking solutions in recovery. Masimo's Opioid Halo and Bridge have shown immense promise in helping opioid users, and we're eager to see their full potential realized. In Masimo’s CEO, Joe Kiani, we've found a passionate voice advocating for overcoming this epidemic, a true thought leader in the recovery field with an unwavering dedication to making a difference.”
Joe Kiani, Founder and CEO of Masimo, added, “We are excited to sponsor Mobilize Recovery, partner with their amazing team, and help kick off the bus tour in September. Masimo is committed to creating evidence-based solutions that fill in existing gaps in patient support networks. We were honored to be chosen by the FDA as a winner of their FDA Opioid Innovation Challenge for our solution to help prevent opioid overdose. With Opioid Halo, we became the first winner to have an authorized device to address the crisis. Bridge, in turn, is the first FDA-cleared medical device to help in the reduction of opioid withdrawal symptoms. Together, we believe these products, and the amazing efforts of Mobilize Recovery and its partners, can make a real difference in fighting the opioid crisis – as well as help eliminate the stigma around addiction.”
Opioid Halo, an opioid overdose prevention and alert system, was granted a De Novo by the FDA in 2023, making it the first and only FDA-cleared monitoring solution for detecting opioid-induced respiratory depression (OIRD). Opioid Halo advances the forefront of continuous monitoring through its unique Opioid Halo engine, an advanced pattern recognition algorithm which helps detect and quantify the risk of severe OIRD. Combined with its innovative distributed architecture, Opioid Halo helps to manage and send escalating alarms to family members, friends, and caregivers, notifying them that help may be needed due to an opioid overdose – including triggering an automatic wellness call, which may lead to EMS being dispatched.
Bridge, a drug-free opioid withdrawal device, uses neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal. Bridge, which has also been granted a De Novo by the FDA, is the first evidence-based, drug-free, non-surgical device of its kind. While medication-assisted treatment can be effective in helping treat opioid withdrawal symptoms, Bridge may help significantly reduce those symptoms, within 30 minutes, helping users make progress in their treatment by bridging the gap on the road to recovery. Bridge fits behind the ear – applied by a healthcare provider in a short, non-surgical procedure – and works by sending electrical impulses to the nerves around the ear, which transmit them to the brain, providing up to five days of continuous relief from withdrawal symptoms.
%2C%20Oct%202024.jpg)
